Want to see FLNA full AI Analyst Report?

Filana Therapeutics (FLNA) Price & Analysis

3,912 Followers

FLNA Stock Chart & Stats

$2.12

-$0.22(-7.28%)

At close: Jan 08 4:00 PM EST

$2.12

-$0.22(-7.28%)

Day’s Range― - ―

52-Week Range$1.16 - $4.98

Previous CloseN/A

VolumeN/A

Average Volume (3M)373.29K

Market Cap

$59.42M

Enterprise Value-$28.12M

Total Cash (Recent Filing)$95.50M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.84

Next Earnings

Aug 05, 2026

EPS Estimate

-0.23

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.96

Shares Outstanding48,307,896

10 Day Avg. Volume337,326

30 Day Avg. Volume373,292

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)1.33

Price to Sales (P/S)0.00

P/FCF Ratio-3.02

Enterprise Value/Market Cap-0.47

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit76.62

Enterprise Value/Ebitda0.61

Forecast

1Y Price Target

$5.00

Price Target Upside135.85% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.88

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Market DemandThere is an unmet medical need for anti-seizure treatment options, suggesting potential demand for new solutions like simufilam.

New OpportunitiesThe company’s licensing of rights from Yale to an issued patent to use of simufilam as a potential treatment for seizures related to rare neurodevelopment disorders is seen as a positive development.

Bears Say

Clinical TrialsResults from the 76-week ReFocus-ALZ Phase 3 trial with simufilam in patients with mild-to-moderate Alzheimer’s disease did not meet the study’s pre-specified endpoints.

Financial RisksInvestment thesis risks include failure of clinical trials to prove efficacy, regulatory requirements for additional clinical studies, and potential need to raise additional funds under poor market conditions.

Filana Therapeutics News

Filana Therapeutics Shareholders Back Board, Compensation Plans

Filana Therapeutics ( ($FLNA) ) has issued an announcement. Filana Therapeutics held its 2026 Annual Meeting of Stockholders...

19d ago

FLNA

BridgeBio, Dave, Marvell, Filana, GE Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($BBIO) ), ( ($DAVE) ), ( ($MRVL) ), ( ($FLNA)...

1M ago

BBIO

Filana Therapeutics resumed with Buy at Maxim on rebranding, strategic pivot

As previously reported, Maxim resumed coverage of Filana Therapeutics (FLNA) with a Buy rating and $5 price target...

1M ago

FLNA

Filana Therapeutics resumed with a Buy at Maxim

Maxim resumed coverage of Filana Therapeutics (FLNA) with a Buy rating and $5 price target Published first on...

1M ago

FLNA

Filana Therapeutics publishes simufilam preclinical data

Filana Therapeutics (FLNA) announced publication in Epilepsia of preclinical data showing that simufilam attenuated seizure progression in a...

3M ago

FLNA

Filana Therapeutics management to meet with Maxim

Meeting to be held on March 24-25 hosted by Maxim. Published first on TheFly – the ultimate source...

4M ago

FLNA

Filana Therapeutics reports Q4 EPS (26c) vs. (57c) last year

“At Filana Therapeutics (FLNA), our name reflects our deep commitment to science and to patients affected by diseases...

4M ago

FLNA

Filana Therapeutics sees 1H26 net cash use in operations $14M-$17M

The Company estimates net cash use in operations for first half of 2026 in a range from $14...

4M ago

FLNA

FLNA FAQ

What was Filana Therapeutics, Inc.’s price range in the past 12 months?

Filana Therapeutics, Inc. lowest stock price was $1.16 and its highest was $4.98 in the past 12 months.

What is Filana Therapeutics, Inc.’s market cap?

Filana Therapeutics, Inc.’s market cap is $59.42M.

When is Filana Therapeutics, Inc.’s upcoming earnings report date?

Filana Therapeutics, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 32 days.

How were Filana Therapeutics, Inc.’s earnings last quarter?

Filana Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.23 by $0.02.

Is Filana Therapeutics, Inc. overvalued?

According to Wall Street analysts Filana Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Filana Therapeutics, Inc. pay dividends?

Filana Therapeutics, Inc. pays a Notavailable dividend of $5.25 which represents an annual dividend yield of N/A. See more information on Filana Therapeutics, Inc. dividends here

What is Filana Therapeutics, Inc.’s EPS estimate?

Filana Therapeutics, Inc.’s EPS estimate is -0.23.

How many shares outstanding does Filana Therapeutics, Inc. have?

Filana Therapeutics, Inc. has 48,307,896 shares outstanding.

What happened to Filana Therapeutics, Inc.’s price movement after its last earnings report?

Filana Therapeutics, Inc. reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.23. Following the earnings report the stock price went down -5.556%.

Which hedge fund is a major shareholder of Filana Therapeutics, Inc.?

Currently, no hedge funds are holding shares in FLNA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Filana Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-99.85%

Trailing 12-Months

Asset Growth

-23.11%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Filana Therapeutics, Inc.

Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.

Filana Therapeutics (FLNA) Earnings & Revenues

Historic Earnings Reports

FLNA Stock 12 Month Forecast

Average Price Target

$5.00

▲(135.85% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","6":"$6","1.5":"$1.5","4.5":"$4.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.5,3,4.5,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.25,1.5384615384615383,1.8269230769230769,2.1153846153846154,2.4038461538461537,2.692307692307692,2.980769230769231,3.269230769230769,3.5576923076923075,3.846153846153846,4.134615384615384,4.423076923076923,4.711538461538462,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.25,1.5384615384615383,1.8269230769230769,2.1153846153846154,2.4038461538461537,2.692307692307692,2.980769230769231,3.269230769230769,3.5576923076923075,3.846153846153846,4.134615384615384,4.423076923076923,4.711538461538462,{"y":5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.25,1.5384615384615383,1.8269230769230769,2.1153846153846154,2.4038461538461537,2.692307692307692,2.980769230769231,3.269230769230769,3.5576923076923075,3.846153846153846,4.134615384615384,4.423076923076923,4.711538461538462,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.85,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.51,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >